Sustained efficacy and quality of life with darolutamide + ADT in mHSPC patients of all ages
Darolutamide demonstrated a significant and consistent high efficacy, positive impact on HRQoL, and minimal burden of treatment-emergent adverse events versus placebo across all age subgroups in patients with metastatic hormone-sensitive prostate cancer (mHSPC).
